[Laboratory and clinical studies on aztreonam in the pediatric field]. 1985

T Hosoda, and M Masuda, and M Miyao

Laboratory and clinical studies were performed as follows on aztreonam (AZT), a new monobactam antibiotic. Pharmacokinetics Serum concentrations of AZT were measured in 1 patient given 20 mg/kg by intravenous bolus injection. The peak concentration was 100 micrograms/ml at 15 minutes, and T 1/2 was 1.85 hours. Clinical efficacy AZT was administrated intravenously to 10 patients in doses of 59.2-170.7 mg/kg (average 76.1 mg/kg) t.i.d. for 3-8 days (average 5.3 days); 5 with pneumonia, 1 with bronchitis, 1 with lymphadenitis, 1 with sepsis (suspected) and 2 with urinary tract infections. The overall efficacy rate was 80%, i.e., efficacy was excellent in 5, good in 3, fair in 1 and poor in 1. Bacteriological efficacy was excellent, i.e., 4 of 4 Gram-negative strains disappeared. Any clinical side effects and laboratory abnormalities were not observed. The above results suggest that AZT is a useful antibiotic for treating pediatric bacterial infections, especially due to Gram-negative bacteria.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005260 Female Females
D006090 Gram-Negative Bacteria Bacteria which lose crystal violet stain but are stained pink when treated by Gram's method. Gram Negative Bacteria
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

T Hosoda, and M Masuda, and M Miyao
November 1985, The Japanese journal of antibiotics,
T Hosoda, and M Masuda, and M Miyao
November 1985, The Japanese journal of antibiotics,
T Hosoda, and M Masuda, and M Miyao
November 1985, The Japanese journal of antibiotics,
T Hosoda, and M Masuda, and M Miyao
November 1985, The Japanese journal of antibiotics,
T Hosoda, and M Masuda, and M Miyao
May 1990, The Japanese journal of antibiotics,
T Hosoda, and M Masuda, and M Miyao
March 1985, The Japanese journal of antibiotics,
T Hosoda, and M Masuda, and M Miyao
June 1989, The Japanese journal of antibiotics,
T Hosoda, and M Masuda, and M Miyao
August 1990, The Japanese journal of antibiotics,
T Hosoda, and M Masuda, and M Miyao
August 1990, The Japanese journal of antibiotics,
T Hosoda, and M Masuda, and M Miyao
December 1985, The Japanese journal of antibiotics,
Copied contents to your clipboard!